Benjamin Braun, MD, PhD

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Benjamin Braun, MD, PhD

Associate Professor in Residence, Department of Pediatrics, UC, San Francisco
Director, Laboratory for Cell Analysis Core, UCSF Helen Diller Family Comprehensive Cancer Center

Phone: (415) 353-2584 (appts)
Box 0106, UCSF
San Francisco, CA 94143-0106

View on UCSF Profiles

Cancer Center Membership

Program Member » Hematopoietic Malignancies» Pediatric Malignancies

Education

Princeton University, A.B., 1990, Molecular Biology
University of California, Los Angeles, Ph.D., 1998, Molecular Biology
University of California, Los Angeles, M.D., 1998, Medicine
University of California, San Francisco, Resident, 1998-2000, Pediatrics
University of California, San Francisco, Fellow, 2000-2003, Hematology/Oncology


Professional Experience

  • 1992-1996
    Graduate Student, Laboratory of Christopher Denny, M.D., University of California, Los Angeles (Project: mechanism of oncogenesis by the Ewing sarcoma fusion protein EWS-FLI)
  • 1998-2000
    Resident, Department of Pediatrics, University of California, San Francisco
  • 2000-2003
    Clinical Fellow, Hematology/Oncology, University of California, San Francisco
  • 2001-present
    Post-doctoral researcher, Laboratory of Kevin Shannon, M.D., University of California, San Francisco (Project: myeloid proliferation and neoplasia initiated by mutant Kras)
  • 2004-2005
    Instructor, Department of Pediatrics, University of California, San Francisco
  • 2005-2007
    Adjunct Assistant Professor, Department of Pediatrics, University of California, San Francisco
  • 2007-2013
    Assistant Professor in Residence, Department of Pediatrics, University of California, San Francisco
  • 2013-present
    Associate Professor in Residence, Department of Pediatrics, University of California, San Francisco

Honors & Awards

  • 1990
    Cum Laude, Princeton University
  • 1990
    Phi Beta Kappa
  • 1990
    Medical Scientist Training Program Fellowship, University of California, Los Angeles
  • 2000-2003
    Campini Fellowship, University of California, San Francisco
  • 2004
    David G. Nathan Award, Society for Pediatric Research
  • 2004
    Melvin Grumbach Pediatric Research Award, UCSF
  • 2005
    Basic Research Scholar American Society of Hematology
  • 2010
    Fellows' Leadership and Advocacy Group Faculty
    Leadership Award, Department of Pediatrics, UCSF

Selected Publications

  1. Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice. J Clin Invest. 2016 Jan 4; 126(1):404.
    View on PubMed
  2. Traxtile: Interactive editing of cell tracks in time-lapse images. Biotechniques. 2014; 59(2):82-6.
    View on PubMed
  3. Subclonal mutations in SETBP1 confer a poor prognosis in juvenile myelomonocytic leukemia. Blood. 2015 Jan 15; 125(3):516-24.
    View on PubMed
  4. PLC-? and PI3K link cytokines to ERK activation in hematopoietic cells with normal and oncogenic Kras. Sci Signal. 2013 Dec 3; 6(304):ra105.
    View on PubMed
  5. Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice. J Clin Invest. 2013 Jan 2; 123(1):335-9.
    View on PubMed
  6. KIT's ship comes in. Blood. 2012 Sep 27; 120(13):2541-2.
    View on PubMed
  7. Targeting oncogenic Ras signaling in hematologic malignancies. Blood. 2012 Oct 25; 120(17):3397-406.
    View on PubMed
  8. A MEK inhibitor abrogates myeloproliferative disease in Kras mutant mice. Sci Transl Med. 2011 Mar 30; 3(76):76ra27.
    View on PubMed
  9. Essential role for Ptpn11 in survival of hematopoietic stem and progenitor cells. Blood. 2011 Apr 21; 117(16):4253-61.
    View on PubMed
  10. Hematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locus. Blood. 2011 Feb 10; 117(6):2022-32.
    View on PubMed
  11. Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia. Nat Genet. 2010 Sep; 42(9):794-800.
    View on PubMed
  12. Mutant Ikzf1, KrasG12D, and Notch1 cooperate in T lineage leukemogenesis and modulate responses to targeted agents. Proc Natl Acad Sci U S A. 2010 Mar 16; 107(11):5106-11.
    View on PubMed
  13. The SPS affair: a complex tale of illicit proliferation. Cancer Cell. 2009 Aug 4; 16(2):87-8.
    View on PubMed
  14. JunB protects against myeloid malignancies by limiting hematopoietic stem cell proliferation and differentiation without affecting self-renewal. Cancer Cell. 2009 Apr 7; 15(4):341-52.
    View on PubMed
  15. Oncogenic Kras initiates leukemia in hematopoietic stem cells. PLoS Biol. 2009 Mar 17; 7(3):e59.
    View on PubMed
  16. Pediatric malignancies: update on sarcomas and leukemia development in children. Curr Opin Genet Dev. 2009 Feb; 19(1):92-6.
    View on PubMed
  17. Targeting Ras in myeloid leukemias. Clin Cancer Res. 2008 Apr 15; 14(8):2249-52.
    View on PubMed
  18. K-RasG12D expression induces hyperproliferation and aberrant signaling in primary hematopoietic stem/progenitor cells. Blood. 2007 May 1; 109(9):3945-52.
    View on PubMed
  19. Somatic activation of a conditional KrasG12D allele causes ineffective erythropoiesis in vivo. Blood. 2006 Sep 15; 108(6):2041-4.
    View on PubMed
  20. Inherited predispositions and hyperactive Ras in myeloid leukemogenesis. Pediatr Blood Cancer. 2006 May 1; 46(5):579-85.
    View on PubMed

Go to UCSF Profiles, powered by CTSI